Selpercatinib

Selpercatinib is a targeted anti-tumor drug targeting RET gene mutations, with significant efficacy and certain safety. However, attention should still be paid to its adverse reactions and contraindications when using it, and reasonable use should be carried out under the guidance of a doctor.

Selpercatinib has shown significant efficacy in treating cancer patients with RET gene mutations. Its objective response rate (ORR) can reach 68% to 85% in different patient populations, and it also shows strong activity in patients with central nervous system (CNS) metastases, with a CNS ORR of up to 91%.

1.Main components

Selpercatinib

2.Adapt to the population

Adult and pediatric patients aged 12 and above.

3.Medication for special populations

3.1Pregnant women and lactation period

Due to the potential impact on the fetus, inform pregnant women of the potential risks to the fetus; Women are advised not to breastfeed during the treatment period with this product and within one week after the last administration.

3.2Geriatric Use

No other clinical issues observed, use under the guidance of a doctor.

3.3Pediatric Use

The safety and efficacy of patients under 12 years old have not been confirmed and should be used with caution.

3.4Patients with renal impairment

It is not recommended to adjust the dosage for patients with mild to severe renal impairment.

3.5Patients with liver damage

Reduce dosage in patients with severe liver function impairment, and do not recommend adjusting dosage in patients with mild to moderate liver impairment.

4.Drug overdose

Drug overdose is not yet clear.

5.Drug storage

Selpercatinib should be stored at room temperature between 20 ° C and 25 ° C (68 ° F and 77 ° F).

6.Pharmacokinetics

The pharmacokinetics of locally advanced or metastatic solid tumor patients were evaluated, and 160mg was administered twice daily unless otherwise specified.

from FDA，2024.06